BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients

  • BeiGene Ltd BGNE announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa (zanubrutinib) to bendamustine and rituximab (B+R).
  • The trial included patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose tumor did not exhibit the deletion of chromosome 17p13.1 (del[17p]).
  • With a median follow-up of 25.8 months, Brukinsa achieved a highly statistically significant improvement in progression-free survival (PFS) compared to B+R, as assessed by an independent review committee, the trial's primary endpoint.
  • In addition, the trial demonstrated a statistically significant improvement in PFS per investigator assessment, a secondary endpoint. 
  • Brukinsa was also generally well-tolerated, consistent with its known safety profile.
  • Price Action: BGNE shares closed at $312.19 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralblood cancerBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!